Literature DB >> 9569077

HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients.

G C Fanning1, K I Welsh, C Bunn, R Du Bois, C M Black.   

Abstract

Systemic sclerosis (SSc) is characterized by the presence of autoantibodies, mostly IgG, which target a limited set of nuclear proteins. These antinuclear antibodies (ANA) associate with disease subgroups and specific organ involvement. Here we show that there is mutual exclusivity of individual ANA in 130 UK SSc patients, confirm clinical associations with antibody profile and extend the analysis to include genetic data. The ANA mutual exclusivity observed leads to the possibility that SSc, in these patients, is in fact three separate diseases. An alternative explanation for exclusivity relates to the fact that optimal production of IgG antibody requires T-cell help, a process restricted by the HLA class II presentation of antigen peptide. If each autoantibody has a different and tight MHC restriction, then there is a possibility that these groups arose from a common pathway and were modified by genetics into the mutually exclusive groups observed, making the separate disease theory less tenable. In order to answer this question, we have determined MHC class II restriction precisely using high-resolution HLA genotyping (SSP) coupled with an amino acid analysis program in our 130 UK SSc patients. DRB1*11 was associated with anti-topoisomerase-I antibody (ATA)-positive patients (P = 0.007) and when combined with ATA (RR = 15.82), dcSSc (RR = 11.45), or both (RR = 21.9), represented the strongest risk factor for pulmonary fibrosis. Patients with antibodies to RNA polymerases I, II and III were associated with DQB1*0201. At the amino acid level, 20 positions in DRB1 and 20 positions in DQB1 showed some significant correlation with an ANA group. Clearly, however, the linkages to MHC class II alleles are not nearly strong enough to explain the mutually exclusive nature of the autoantibody groups and our results support, but do not prove, the separate disease theory.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569077     DOI: 10.1093/rheumatology/37.2.201

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  27 in total

Review 1.  Systemic sclerosis: an autoantibody mosaic.

Authors:  C C Bunn; C M Black
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

3.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Authors:  M Binks; J R Passweg; D Furst; P McSweeney; K Sullivan; C Besenthal; J Finke; H H Peter; J van Laar; F C Breedveld; W E Fibbe; D Farge; E Gluckman; F Locatelli; A Martini; F van den Hoogen; L van de Putte; A V Schattenberg; R Arnold; P A Bacon; P Emery; I Espigado; B Hertenstein; F Hiepe; A Kashyap; I Kötter; A Marmont; A Martinez; M J Pascual; A Gratwohl; H G Prentice; C Black; A Tyndall
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

4.  Mapping of the immunodominant T cell epitopes of the protein topoisomerase I.

Authors:  S Veeraraghavan; E A Renzoni; H Jeal; M Jones; J Hammer; A U Wells; C M Black; K I Welsh; R M du Bois
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

Review 5.  Unraveling the genetic component of systemic sclerosis.

Authors:  José Ezequiel Martín; Lara Bossini-Castillo; Javier Martín
Journal:  Hum Genet       Date:  2012-01-05       Impact factor: 4.132

6.  Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma.

Authors:  Eleni Tiniakou; Andrea Fava; Zsuzsanna H McMahan; Tara Guhr; Robert N O'Meally; Ami A Shah; Fredrick M Wigley; Robert N Cole; Francesco Boin; Erika Darrah
Journal:  Arthritis Rheumatol       Date:  2020-06-26       Impact factor: 10.995

7.  Evaluation of liver function tests in scleroderma patients.

Authors:  Gehan Ibrahim Abdelrazek Salem; Awni Ali Abdulrahman
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

8.  What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases.

Authors:  Jacqueline E Oliver; Alan J Silman
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.

Authors:  Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille
Journal:  Ann Rheum Dis       Date:  2009-07-12       Impact factor: 19.103

Review 10.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.